CI Jan 2025 320.000 put
| Previous close | 5.20 |
| Open | 5.20 |
| Bid | 7.10 |
| Ask | 8.20 |
| Strike | 320.00 |
| Expiry date | 2025-01-17 |
| Day's range | 5.20 - 5.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 329 |
PR NewswireEvernorth announces another step forward in lowering drug prices by making a Stelara biosimilar available at $0 out of pocket for patients early next year
Evernorth Health Services announced that it plans to have a Stelara biosimilar available for $0 out of pocket for eligible patients of its specialty pharmacy, Accredo, beginning in early 2025. The interchangeable biosimilar will be produced for Evernorth's affiliate private label distributor, Quallent Pharmaceuticals. It will be available at $0 out of pocket for most patients through Quallent's copay assistance program. This program is expected to save individual patients around $4,000 on averag
Investor's Business DailyCigna Group Stock Flashing Renewed Technical Strength
Cigna Group shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 74 to 81.
Insider MonkeyIs The Cigna Group (CI) The Best Dividend Paying Stock To Buy According to Quant Hedge Fund AQR?
We recently published a list of 10 Best Dividend Paying Stocks To Buy According to Quant Hedge Fund AQR. In this article, we are going to take a look at where The Cigna Group (NYSE:CI) stands against the other dividend-paying stocks to buy according to Quant Hedge Fund AQR. Only a handful of hedge funds have […]
